| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.24 | 1e-13 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-09 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.24 | 9e-07 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |